Robotic Surgery for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores two methods of robotic surgery for individuals with early-stage non-small cell lung cancer (NSCLC). Totally Robotic Lung Resection allows the surgeon to perform the entire procedure using robotic tools, while Surgeon-Assisted Robotic Lung Resection involves the surgeon using handheld tools with robotic assistance. The trial aims to determine which method is more cost-effective and beneficial for patients. Suitable candidates have stage I, II, or IIIa NSCLC and qualify for robotic thoracoscopic surgery, a minimally invasive procedure with robotic assistance. As an unphased trial, it provides patients the chance to contribute to innovative surgical techniques that could enhance future treatment options.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are unable to stop anticoagulant therapy (blood thinners) before surgery.
What prior data suggests that robotic-assisted thoracoscopic surgery is safe for lung cancer patients?
Research has shown that robotic lung surgeries, like those in this study, are generally safe. Studies have found that these surgeries often lead to fewer complications and less blood loss. Patients typically spend less time in the hospital, indicating a smoother recovery.
For the Totally Robotic approach, data indicates it is well-tolerated, with low complication rates and successful outcomes in lung cancer surgeries. The tools used, such as robotic staplers and energy devices, are designed for precision and safety.
In summary, both robotic methods in this trial have safety records suggesting they are well-tolerated by patients. While every surgery carries risks, the evidence so far reassures those considering participation.12345Why are researchers excited about this trial?
Researchers are excited about robotic lung resections for lung cancer because they offer a high-tech approach to surgery that could enhance precision and recovery. Unlike traditional open or video-assisted thoracoscopic surgery (VATS), these robotic techniques use advanced tools like the Da Vinci Vessel Sealer Extend Energy Device and SureForm Stapler, which can improve surgical precision and reduce human error. The totally robotic approach allows for less invasive procedures by fully utilizing robotic arms, potentially leading to quicker recovery times and less postoperative pain. Meanwhile, the surgeon-assisted approach combines robotic precision with a surgeon’s expertise, which might offer a balanced advantage of both human oversight and robotic accuracy. These innovations could significantly improve the surgical outcomes for lung cancer patients.
What evidence suggests that this trial's treatments could be effective for early-stage non-small cell lung cancer?
Research has shown that robotic lung surgery can improve recovery for patients with early-stage non-small cell lung cancer (NSCLC). This trial will compare two robotic surgery techniques: Totally Robotic Lung Resection and Surgeon-Assisted Robotic Lung Resection. Studies have found that robotic lobectomy, which involves removing part of the lung, often results in fewer postoperative complications than traditional methods. Patients who underwent robotic surgery generally had similar survival rates to those who had open or video-assisted surgeries. Additionally, robotic techniques may more effectively remove leftover cancer cells after tumor reduction. Overall, these findings suggest that robotic lung surgery is a promising option for NSCLC patients.678910
Who Is on the Research Team?
Waël C Hanna, MDCM MBA FRCSC
Principal Investigator
St. Joseph's Healthcare Hamilton
Are You a Good Fit for This Trial?
This trial is for patients with early-stage non-small cell lung cancer (NSCLC). Participants should be suitable candidates for robotic-assisted thoracoscopic surgery (RTS) but have not yet undergone the procedure. Specific eligibility criteria are not provided, so it's important to consult with the study team for detailed requirements.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo robotic-assisted thoracoscopic surgery (RTS) for early-stage non-small cell lung cancer (NSCLC) using either Totally Robotic or Surgeon-Assisted methods
Follow-up
Participants are monitored for intraoperative complications, adverse events, and other clinical outcomes post-surgery
Cost Evaluation
Evaluation of surgical device costs and inpatient hospitalization costs
What Are the Treatments Tested in This Trial?
Interventions
- Surgeon-Assisted Robotic Lung Resection
- Totally Robotic Lung Resection
Trial Overview
The trial compares two methods of performing RTS: Totally Robotic lung resection using Vessel Sealer Extend and SureForm staplers versus Surgeon-Assisted resection using Medtronic Signia stapler. The goal is to assess differences in costs and patient outcomes between these techniques during NSCLC surgery.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Patients randomized to this arm will undergo RTS with the Da Vinci Vessel Sealer Extend Energy Device and SureForm Stapler.
Patients randomized to this arm will undergo RTS with the Medtronic Signia Stapler.
Find a Clinic Near You
Who Is Running the Clinical Trial?
St. Joseph's Healthcare Hamilton
Lead Sponsor
Published Research Related to This Trial
Citations
Outcomes of robotic lobectomy for non-small cell lung ...
RL for NSCLC performed in an NCI-CCC appears to have improved perioperative outcomes with comparable long-term OS compared to national benchmarks in OL and VL.
Comparison of Robotic and Open Lobectomy for Lung Cancer ...
The objective of this study was to evaluate the impact of the robotic technique on the postoperative outcomes of patients with poor lung ...
Long-term outcomes of robotic versus video-assisted ...
Long-term outcomes of robotic versus video-assisted pulmonary lobectomy for non-small cell lung cancer: systematic review and meta-analysis ...
A dual approach to lung cancer management
In this way, it is more favorable to eliminate the rest of the cancer cells after the robotic surgery has reduced the size of the tumor and brought the ...
Uniportal Robotic Lobectomy and Lymphadenectomy for ...
The clinical data of 34 consecutive patients with lung cancer who underwent improved uniportal robotic-assisted thoracoscopic surgery (uRATS) at ...
The long-term survival of robotic lobectomy for non-small cell ...
The latter has been shown to be safe and effective for pulmonary lobectomy for lung cancer with intraoperative and short-term postoperative metrics such as ...
Robotic anatomic pulmonary resection—the data - Watkins
Existing data suggest that RL offers numerous advantages, such as reduced complications, minimal blood loss, shorter hospital stays, and lower ...
The Safety of Robotic Pneumonectomy
Robot-assisted pneumonectomy can be performed safely in the setting of appropriate oncologic indications. Patients have comparable rates of R0 resection, nodal ...
Video-Assisted vs Robotic-Assisted Lung Lobectomies for ...
This cohort study of 1088 patients aged 18 to 90 years found that the median robotic-assisted adjusted operative duration was 20.6 minutes longer than that for ...
A Brief Report on Survival After Robotic Lobectomy for ...
The 5-year recurrence of disease risk and overall survival were 24.9% and 83.2%, respectively, in the open group and 24.6% and 86.1%, respectively, in the ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.